Skip to search formSkip to main contentSkip to account menu

bectumomab

Known as: IMMU-LL2-Fab, MAb LL2 (EPB2), monoclonal antibody IMMU-LL2-Fab 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Structure-based reverse vaccinology (RV) (Van Regenmortel 2011a) attempts to develop an HIV-1 vaccine by determining the 3-D… 
2008
2008
On January 1, 2000, Medicare extended the coverage of immunosuppression medications from 3 years to life for elderly and disabled… 
Review
2008
Review
2008
Our immune system constantly interacts with our internal environment, protects us from our external environment and provides the… 
Highly Cited
2004
Highly Cited
2004
Mangeat B, Turelli P, Caron G, et al. Nature. 2003;424:99–102 Innate intracellular antiretroviral defense mechanisms have been… 
2003
2003
A unique opportunity to develop world class infection and health protection services for children The Chief Medical Officer (CMO… 
2002
2002
UNLABELLED The efficacy of a Tc99m-labeled anti-lymphoma antibody fragment, bectumomab [LymphoScan], was retrospectively examined… 
1996
1996
Dr. Hatem Mansy, Senior Consultant Nephrologist, North West Armed Forces, Hospitals Program, Tabuk (Saudi Arabia) Dear Sir… 
Review
1992
Review
1992
The reason why the NCI Workshop on Investigational Strat egies for Detection and Intervention in Early Lung Cancer was convened… 
1990
1990
IN this study in part of Fife, parents of children under 5 were interviewed about pertussis immunisation. Fifteen per cent of the…